Lo, J.A.; Fisher, D.E. The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. Science 2014, 346, 945–949, doi:10.1126/science.1253735.
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA. Cancer J. Clin. 2020, 70, 7–30, doi:10.3322/caac.21590.
Millet, A.; Martin, A.R.; Ronco, C.; Rocchi, S.; Benhida, R. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Med. Res. Rev. 2017, 37, 98–148, doi:10.1002/med.21404.
PDQ Adult Treatment Editorial Board Melanoma Treatment (PDQ®). Health Professional Version. In PDQ Cancer Information Summaries; National Cancer Institute (US): Bethesda, MD, USA, 2002.
Davey, R.J.; van der Westhuizen, A.; Bowden, N.A. Metastatic melanoma treatment: Combining old and new therapies. Crit. Rev. Oncol. Hematol. 2016, 98, 242–253, doi:10.1016/j.critrevonc.2015.11.011.
Amaral, T.; Sinnberg, T.; Meier, F.; Krepler, C.; Levesque, M.; Niessner, H.; Garbe, C. The mitogen-activated protein kinase pathway in melanoma part I—Activation and primary resistance mechanisms to BRAF inhibition. Eur. J. Cancer Oxf. Engl. 1990 2017, 73, 85–92, doi:10.1016/j.ejca.2016.12.010.
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674, doi:10.1016/j.cell.2011.02.013.
Westermark, U.K.; Wilhelm, M.; Frenzel, A.; Henriksson, M.A. The MYCN oncogene and differentiation in neuroblastoma. Semin. Cancer Biol. 2011, 21, 256–266, doi:10.1016/j.semcancer.2011.08.001.
Yuneva, M.; Zamboni, N.; Oefner, P.; Sachidanandam, R.; Lazebnik, Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 2007, 178, 93–105, doi:10.1083/jcb.200703099.
Son, J.; Lyssiotis, C.A.; Ying, H.; Wang, X.; Hua, S.; Ligorio, M.; Perera, R.M.; Ferrone, C.R.; Mullarky, E.; Shyh-Chang, N.; et al. Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway. Nature 2013, 496, 101–105, doi:10.1038/nature12040.
Gaglio, D.; Metallo, C.M.; Gameiro, P.A.; Hiller, K.; Danna, L.S.; Balestrieri, C.; Alberghina, L.; Stephanopoulos, G.; Chiaradonna, F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 2011, 7, 523, doi:10.1038/msb.2011.56.
Shestov, A.A.; Mancuso, A.; Lee, S.-C.; Guo, L.; Nelson, D.S.; Roman, J.C.; Henry, P.-G.; Leeper, D.B.; Blair, I.A.; Glickson, J.D. Bonded Cumomer Analysis of Human Melanoma Metabolism Monitored by 13C NMR Spectroscopy of Perfused Tumor Cells. J. Biol. Chem. 2016, 291, 5157–5171, doi:10.1074/jbc.M115.701862.
Schwartz, L.; Supuran, C.T.; Alfarouk, K.O. The Warburg Effect and the Hallmarks of Cancer. Anticancer Agents Med. Chem. 2017, 17, 164–170, doi:10.2174/1871520616666161031143301.
Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218, doi:10.1016/j.tibs.2015.12.001.
Ashton, T.M.; McKenna, W.G.; Kunz-Schughart, L.A.; Higgins, G.S. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2018, 24, 2482–2490, doi:10.1158/1078-0432.CCR-17-3070.
Yang, L.; Venneti, S.; Nagrath, D. Glutaminolysis: A Hallmark of Cancer Metabolism. Annu. Rev. Biomed. Eng. 2017, 19, 163–194, doi:10.1146/annurev-bioeng-071516-044546.
Khamari, R.; Trinh, A.; Gabert, P.E.; Corazao-Rozas, P.; Riveros-Cruz, S.; Balayssac, S.; Malet-Martino, M.; Dekiouk, S.; Joncquel Chevalier Curt, M.; Maboudou, P. et al. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death Dis. 2018, 9, doi:10.1038/s41419-018-0340-4.
Beger, R.D. A Review of Applications of Metabolomics in Cancer. Metabolites 2013, 3, 552–574, doi:10.3390/metabo3030552.
Wishart, D.S.; Mandal, R.; Stanislaus, A.; Ramirez-Gaona, M. Cancer Metabolomics and the Human Metabolome Database. Metabolites 2016, 6, 10, doi:10.3390/metabo6010010.
Puchades-Carrasco, L.; Pineda-Lucena, A. Metabolomics Applications in Precision Medicine: An Oncological Perspective. Curr. Top. Med. Chem. 2017, 17, 2740–2751, doi:10.2174/1568026617666170707120034.
Hernandez-Davies, J.E.; Tran, T.Q.; Reid, M.A.; Rosales, K.R.; Lowman, X.H.; Pan, M.; Moriceau, G.; Yang, Y.; Wu, J.; Lo, R.S. et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J. Transl. Med. 2015, 13, 210, doi:10.1186/s12967-015-0581-2.
Corazao-Rozas, P.; Guerreschi, P.; André, F.; Gabert, P.-E.; Lancel, S.; Dekiouk, S.; Fontaine, D.; Tardivel, M.; Savina, A.; Quesnel, B.; et al. Mitochondrial oxidative phosphorylation controls cancer cell’s life and death decisions upon exposure to MAPK inhibitors. Oncotarget 2016, 7, 39473–39485, doi:10.18632/oncotarget.7790.
Baenke, F.; Chaneton, B.; Smith, M.; Van Den Broek, N.; Hogan, K.; Tang, H.; Viros, A.; Martin, M.; Galbraith, L.; Girotti, M.R.; et al. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol. Oncol. 2016, 10, 73–84, doi:10.1016/j.molonc.2015.08.003.
Luebker, S.A.; Koepsell, S.A. Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Front. Oncol. 2019, 9, doi:10.3389/fonc.2019.00268.
Rossi, A.; Roberto, M.; Panebianco, M.; Botticelli, A.; Mazzuca, F.; Marchetti, P. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. Eur. J. Pharmacol. 2019, 862, 172621, doi:10.1016/j.ejphar.2019.172621.
Najem, A.; Krayem, M.; Salès, F.; Hussein, N.; Badran, B.; Robert, C.; Awada, A.; Journe, F.; Ghanem, G.E. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. Eur. J. Cancer Oxf. Engl. 1990 2017, 83, 154–165, doi:10.1016/j.ejca.2017.06.033.
Krayem, M.; Najem, A.; Journe, F.; Morandini, R.; Sales, F.; Awada, A.; Ghanem, G.E. Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. Oncotarget 2018, 9, 31888–31903, doi:10.18632/oncotarget.25879.
Najem, A.; Krayem, M.; Perdrix, A.; Kerger, J.; Awada, A.; Journe, F.; Ghanem, G. New Drug Combination Strategies in Melanoma: Current Status and Future Directions. Anticancer Res. 2017, 37, 5941–5953, doi:10.21873/anticanres.12041.
Wang, J.; Ji, H.; Niu, X.; Yin, L.; Wang, Y.; Gu, Y.; Li, D.; Zhang, H.; Lu, M.; Zhang, F. et al. Sodium- Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer. Dis. Markers 2020, 2020, 6103542, doi:10.1155/2020/6103542.
Locasale, J.W.; Cantley, L.C. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011, 14, 443–451, doi:10.1016/j.cmet.2011.07.014.
Richtig, G.; Hoeller, C.; Kashofer, K.; Aigelsreiter, A.; Heinemann, A.; Kwong, L.N.; Pichler, M.; Richtig, E. Beyond the BRAFV600E hotspot: Biology and clinical implications of rare BRAF gene mutations in melanoma patients. Br. J. Dermatol. 2017, 177, 936–944, doi:10.1111/bjd.15436.
Muñoz-Couselo, E.; Adelantado, E.Z.; Ortiz, C.; García, J.S.; Perez-Garcia, J. NRAS-mutant melanoma: Current challenges and future prospect. OncoTargets Ther. 2017, 10, 3941–3947, doi:10.2147/OTT.S117121.
Lerner, B.A.; Stewart, L.A.; Horowitz, D.P.; Carvajal, R.D. Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive Disease. Oncol. Williston Park N 2017, 31, e23–e32.
Hirschhaeuser, F.; Sattler, U.G.A.; Mueller-Klieser, W. Lactate: A Metabolic Key Player in Cancer. Cancer Res. 2011, 71, 6921–6925, doi:10.1158/0008-5472.CAN-11-1457.
Marignac, V.M.; Smith, S.; Toban, N.; Bazile, M.; Aloyz, R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. Oncotarget 2013, 4, 2550–2566.
Altman, B.J.; Stine, Z.E.; Dang, C.V. From Krebs to clinic: Glutamine metabolism to cancer therapy. Nat. Rev. Cancer 2016, 16, 749, doi:10.1038/nrc.2016.114.
Altinok, O.; Poggio, J.L.; Stein, D.E.; Bowne, W.B.; Shieh, A.C.; Snyder, N.W.; Orynbayeva, Z. Malate-aspartate shuttle promotes l-lactate oxidation in mitochondria. J. Cell. Physiol. 2020, 235, 2569–2581, doi:10.1002/jcp.29160.
Allen, E.L.; Ulanet, D.B.; Pirman, D.; Mahoney, C.E.; Coco, J.; Si, Y.; Chen, Y.; Huang, L.; Ren, J.; Choe, S.; et al. Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. Cell Rep. 2016, 17, 876–890, doi:10.1016/j.celrep.2016.09.052.
Luís, R.; Brito, C.; Pojo, M. Melanoma Metabolism: Cell Survival and Resistance to Therapy. Adv. Exp. Med. Biol. 2020, 1219, 203–223, doi:10.1007/978-3-030-34025-4_11.
Haq, R.; Fisher, D.E. Biology and Clinical Relevance of the Micropthalmia Family of Transcription Factors in Human Cancer. J. Clin. Oncol. 2011, 29, 3474–3482, doi:10.1200/JCO.2010.32.6223.
Garcia-Bermudez, J.; Baudrier, L.; La, K.; Zhu, X.G.; Fidelin, J.; Sviderskiy, V.O.; Papagiannakopoulos, T.; Molina, H.; Snuderl, M.; Lewis, C.A.; et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 2018, 20, 775–781, doi:10.1038/s41556-018-0118-z.
Muñoz-Pinedo, C.; El Mjiyad, N.; Ricci, J.-E. Cancer metabolism: Current perspectives and future directions. Cell Death Dis. 2012, 3, e248, doi:10.1038/cddis.2011.123.
Little, A.S.; Balmanno, K.; Sale, M.J.; Newman, S.; Dry, J.R.; Hampson, M.; Edwards, P.A.W.; Smith, P.D.; Cook, S.J. A correction to the research article titled: “Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells”. Sci. Signal. 2011, 4, er2, doi:10.1126/scisignal.4170er2.
Patel, H.; Yacoub, N.; Mishra, R.; White, A.; Yuan, L.; Alanazi, S.; Garrett, J.T. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers 2020, 12, doi:10.3390/cancers12020482.
Trunzer, K.; Pavlick, A.C.; Schuchter, L.; Gonzalez, R.; McArthur, G.A.; Hutson, T.E.; Moschos, S.J.; Flaherty, K.T.; Kim, K.B.; Weber, J.S.; et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31, 1767– 1774, doi:10.1200/JCO.2012.44.7888.
Saha, S.K.; Islam, S.M.R.; Abdullah-AL-Wadud, M.; Islam, S.; Ali, F.; Park, K.S. Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer. J. Clin. Med. 2019, 8, 355, doi:10.3390/jcm8030355.
Matés, J.M.; Segura, J.A.; Martín-Rufián, M.; Campos-Sandoval, J.A.; Alonso, F.J.; Márquez, J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr. Mol. Med. 2013, 13, 514–534, doi:10.2174/1566524011313040005.
Matés, J.M.; Campos-Sandoval, J.A.; de Santos-Jiménez, J.L.; Márquez, J. Dysregulation of glutaminase and glutamine synthetase in cancer. Cancer Lett. 2019, 467, 29–39, doi:10.1016/j.canlet.2019.09.011.
Petővári, G.; Dankó, T.; Krencz, I.; Hujber, Z.; Rajnai, H.; Vetlényi, E.; Raffay, R.; Pápay, J.; Jeney, A.; Sebestyén, A. Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. Pathol. Oncol. Res. POR 2019, doi:10.1007/s12253-019-00677-2.
Jacque, N.; Ronchetti, A.M.; Larrue, C.; Meunier, G.; Birsen, R.; Willems, L.; Saland, E.; Decroocq, J.; Maciel, T.T.; Lambert, M.; et al. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood 2015, 126, 1346–1356, doi:10.1182/blood-2015-01-621870.
Rai, Y.; Yadav, P.; Kumari, N.; Kalra, N.; Bhatt, A.N. Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin. Biosci. Rep. 2019, 39, doi:10.1042/BSR20190880.
Lee, H.-J.; Li, C.-F.; Ruan, D.; He, J.; Montal, E.D.; Lorenz, S.; Girnun, G.D.; Chan, C.-H. Non-proteolytic ubiquitination of Hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion. Nat. Commun. 2019, 10, 2625, doi:10.1038/s41467-019-10374-y.
Schepkens, C.; Dallons, M.; Dehairs, J.; Talebi, A.; Jeandriens, J.; Drossart, L.-M.; Auquier, G.; Tagliatti, V.; Swinnen, J.V.; Colet, J.-M. A New Classification Method of Metastatic Cancers Using a 1H-NMR-Based Approach: A Study Case of Melanoma, Breast, and Prostate Cancer Cell Lines. Metabolites 2019, 9, doi:10.3390/metabo9110281.
Iorio, E.; Caramujo, M.J.; Cecchetti, S.; Spadaro, F.; Carpinelli, G.; Canese, R.; Podo, F. Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer. Front. Oncol. 2016, 6, 205, doi:10.3389/fonc.2016.00205.
Lin, X.-M.; Hu, L.; Gu, J.; Wang, R.-Y.; Li, L.; Tang, J.; Zhang, B.-H.; Yan, X.-Z.; Zhu, Y.-J.; Hu, C.-L. et al. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression. Gastroenterology 2017, 152, 1187–1202, doi:10.1053/j.gastro.2016.12.033.
Glunde, K.; Bhujwalla, Z.M.; Ronen, S.M. Choline metabolism in malignant transformation. Nat. Rev. Cancer 2011, 11, 835–848, doi:10.1038/nrc3162.
Yang, L.; Yu, D.; Mo, R.; Zhang, J.; Hua, H.; Hu, L.; Feng, Y.; Wang, S.; Zhang, W.-Y.; Yin, N.; et al. The Succinate Receptor GPR91 Is Involved in Pressure Overload-Induced Ventricular Hypertrophy. PLoS ONE 2016, 11, e0147597, doi:10.1371/journal.pone.0147597.
Jin, L.; Alesi, G.N.; Kang, S. Glutaminolysis as a target for cancer therapy. Oncogene 2016, 35, 3619–3625, doi:10.1038/onc.2015.447.
Thompson, R.M.; Dytfeld, D.; Reyes, L.; Robinson, R.M.; Smith, B.; Manevich, Y.; Jakubowiak, A.; Komarnicki, M.; Przybylowicz-Chalecka, A.; Szczepaniak, T.; et al. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget 2017, 8, 35863–35876, doi:10.18632/oncotarget.16262.
Qie, S.; Yoshida, A.; Parnham, S.; Oleinik, N.; Beeson, G.C.; Beeson, C.C.; Ogretmen, B.; Bass, A.J.; Wong, K.-K.; Rustgi, A.K.; et al. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat. Commun. 2019, 10, 1296, doi:10.1038/s41467-019-09179- w.
Guo, L.; Zhou, B.; Liu, Z.; Xu, Y.; Lu, H.; Xia, M.; Guo, E.; Shan, W.; Chen, G.; Wang, C. Blockage of glutaminolysis enhances the sensitivity of ovarian cancer cells to PI3K/mTOR inhibition involvement of STAT3 signaling. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 11007–11015, doi:10.1007/s13277-016- 4984-3.
Marchetti, P.; Guerreschi, P.; Mortier, L.; Kluza, J. Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics. Int. J. Cell Biol. 2015, 2015, 283145, doi:10.1155/2015/283145.
Colapietro, A.; Gravina, G.L.; Petragnano, F.; Fasciani, I.; Scicchitano, B.M.; Beirinckx, F.; Pujuguet, P.; Saniere, L.; Van der Aar, E.; Musio, D.; et al. Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines In Vitro and In Vivo. J. Oncol. 2020, 2020, 9342732, doi:10.1155/2020/9342732.
Ishigaki, H.; Minami, T.; Morimura, O.; Kitai, H.; Horio, D.; Koda, Y.; Fujimoto, E.; Negi, Y.; Nakajima, Y.; Niki, M.; et al. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest. Biochem. Biophys. Res. Commun. 2019, 519, 846–853, doi:10.1016/j.bbrc.2019.09.076.
Human Metabolome Database. Available online: https://hmdb.ca/(accessed on 24 March 2020).
Functional Proteomics RPPA Core Facility. Available online: https://www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-core.html (accessed on 24 March 2020).
HuRI. Home. Available online: http://www.interactome-atlas.org/(accessed on 24 March 2020).
Metabo Analyst. Available online: https://www.metaboanalyst.ca/(accessed on 24 March 2020).
